PMID- 34230610
OWN - NLM
STAT- MEDLINE
DCOM- 20211217
LR  - 20221017
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 125
IP  - 6
DP  - 2021 Sep
TI  - Association between post-treatment circulating biomarkers of inflammation and 
      survival among stage II-III colorectal cancer patients.
PG  - 806-815
LID - 10.1038/s41416-021-01458-y [doi]
AB  - BACKGROUND: Biomarker studies on colorectal cancer (CRC) prognosis are limited to 
      pre-diagnostic or pre-operative measures. Post-treatment biomarkers are not well 
      understood for their associations with CRC survival. METHODS: We included 306 
      eligible incident stage II-III CRC cases from the population-based Seattle Colon 
      Cancer Family Registry. Concentrations of C-reactive protein (CRP), interleukin-6 
      (IL-6), monocyte chemoattractant protein-1 (MCP-1), adiponectin, and leptin were 
      measured using post-treatment plasma samples. Adjusted hazard ratios (HRs) and 
      95% confidence intervals (CIs) for all-cause and CRC-specific mortality were 
      calculated using Cox proportional hazard models. RESULTS: Elevated levels of CRP, 
      IL-6, MCP-1, and adiponectin were significantly associated with a higher risk of 
      all-cause mortality within 10 years post blood draw with HRs (95% CI) of 1.32 
      (1.10-2.59), 2.72 (2.07-3.56), 1.97 (1.18-3.28) and 1.71 (1.14-2.58), 
      respectively. IL-6 and adiponectin had a dose-response effect 
      (P(trend) < 0.0001). For CRC-specific mortality, we observed positive 
      associations for CRP (HR = 1.75, 95% CI: 1.2-2.56), IL-6 (HR = 5.02, 95% CI: 
      2.92-8.59), MCP-1 (HR = 3.78, 95% CI: 1.41-10.08), and adiponectin (HR = 3.16, 
      95% CI: 1.27-7.86), and inverse association for leptin (HR = 0.44, 95% CI: 
      0.29-0.68) within the first year of blood draw, whereas the association for IL-6 
      remained statistically significant over 10 years. CONCLUSION: Our results support 
      the role of chronic inflammation in CRC progression and suggested several 
      post-treatment inflammatory biomarkers, particularly IL-6, are promising 
      prognostic markers for stage II-III CRC patients.
CI  - (c) 2021. This is a U.S. government work and not under copyright protection in the 
      U.S.; foreign copyright protection may apply.
FAU - Hua, Xinwei
AU  - Hua X
AUID- ORCID: 0000-0003-2114-2975
AD  - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
      WA, USA.
AD  - University of Washington, Seattle, WA, USA.
AD  - Clinical and Translational Epidemiology Unit and Division of Gastroenterology, 
      Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
FAU - Kratz, Mario
AU  - Kratz M
AD  - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
      WA, USA.
AD  - University of Washington, Seattle, WA, USA.
FAU - Malen, Rachel C
AU  - Malen RC
AD  - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
      WA, USA.
FAU - Dai, James Y
AU  - Dai JY
AD  - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
      WA, USA.
AD  - University of Washington, Seattle, WA, USA.
FAU - Lindstrom, Sara
AU  - Lindstrom S
AD  - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
      WA, USA.
AD  - University of Washington, Seattle, WA, USA.
FAU - Zheng, Yingye
AU  - Zheng Y
AD  - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
      WA, USA.
AD  - University of Washington, Seattle, WA, USA.
FAU - Newcomb, Polly A
AU  - Newcomb PA
AUID- ORCID: 0000-0001-8786-0043
AD  - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
      WA, USA. pnewcomb@fredhutch.org.
AD  - University of Washington, Seattle, WA, USA. pnewcomb@fredhutch.org.
LA  - eng
GR  - K05 CA152715/CA/NCI NIH HHS/United States
GR  - U01 CA167551/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20210706
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (ADIPOQ protein, human)
RN  - 0 (Adiponectin)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (IL6 protein, human)
RN  - 0 (Interleukin-6)
RN  - 0 (LEP protein, human)
RN  - 0 (Leptin)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adiponectin/*blood
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/blood
MH  - C-Reactive Protein/*analysis
MH  - Case-Control Studies
MH  - Chemokine CCL2/*blood
MH  - Colorectal Neoplasms/blood/mortality/*pathology
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Interleukin-6/*blood
MH  - Leptin/*blood
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Survival Analysis
PMC - PMC8438064
COIS- The authors declare no competing interests.
EDAT- 2021/07/08 06:00
MHDA- 2021/12/18 06:00
PMCR- 2022/07/06
CRDT- 2021/07/07 06:52
PHST- 2020/10/07 00:00 [received]
PHST- 2021/06/02 00:00 [accepted]
PHST- 2021/05/09 00:00 [revised]
PHST- 2021/07/08 06:00 [pubmed]
PHST- 2021/12/18 06:00 [medline]
PHST- 2021/07/07 06:52 [entrez]
PHST- 2022/07/06 00:00 [pmc-release]
AID - 10.1038/s41416-021-01458-y [pii]
AID - 1458 [pii]
AID - 10.1038/s41416-021-01458-y [doi]
PST - ppublish
SO  - Br J Cancer. 2021 Sep;125(6):806-815. doi: 10.1038/s41416-021-01458-y. Epub 2021 
      Jul 6.